Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

• Status: Completed
• Trial end date: 2018-08-23
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine T-cell mediated inflammatory immune response in some participants previously exposed to atabecestat.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Janssen Research & Development, LLC

Criteria

Inclusion Criteria:

• Participant who received and discontinued atabecestat in one of the following prior trials (54861911ALZ2002, 54861911ALZ2003, or 54861911ALZ2004)

• Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study

• Willing and able to adhere to the prohibitions and restrictions specified for this study

Exclusion Criteria:

• Anemic based on the last blood draw in the prior atabecestat trial

• Donated more than (>) 450 milliliter (mL) of blood in the past 3 months

• Currently participating in an atabecestat study (54861911ALZ2002, 54861911ALZ2003, or 54861911ALZ2004)